

# Special Issue

## End-of-Life Cancer Care

### Message from the Guest Editor

Despite advances in cancer therapies, there are increasing controversies about the interface between active and palliative measures. For clinicians, there is a dilemma often about how to manage someone receiving active disease-modifying treatment, yet, at the same time, to acknowledge and support the patient and their family to deal with bigger issues, such as goals of care, that might not include cure; to consider and prepare for the possibility of death and yet to not destroy hope. There are challenges about how and when to introduce a palliative focus to care and controversies about who should not only have these conversations but who should be the coordinator of this care. This Special Issue will focus on the end of life cancer care needs of patients, families, and clinicians, living and dying with cancer.

---

### Guest Editor

Prof. Dr. Gregory Crawford

1. Senior Consultant in Palliative Medicine and Director of Research & Education, Northern Adelaide Palliative Service, Modbury, SA 5092, Australia
2. Professor of Palliative Medicine, Discipline of Medicine, University of Adelaide, Adelaide, SA 5005, Australia

---

### Deadline for manuscript submissions

closed (31 July 2016)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/6034](http://mdpi.com/si/6034)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](http://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)